A UK-based resource to support the monitoring and safe use of anti-TB drugs and second-line treatment of multidrug-resistant TB

Using the best available evidence and expert consensus, this document provides guidance for adverse effect monitoring in multidrug-resistant TB (MDR-TB). It includes recommendations for baseline tests, routine drug and toxicity monitoring guides as well as individual drug monographs for all drugs cu...

Descripción completa

Detalles Bibliográficos
Autores principales: Potter, J L, Capstick, T, Ricketts, W M, Whitehead, N, Kon, O M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2015
Materias:
Chest Clinic
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4345768/
https://www.ncbi.nlm.nih.gov/pubmed/24928813
http://dx.doi.org/10.1136/thoraxjnl-2014-205278
Descripción
Sumario:Using the best available evidence and expert consensus, this document provides guidance for adverse effect monitoring in multidrug-resistant TB (MDR-TB). It includes recommendations for baseline tests, routine drug and toxicity monitoring guides as well as individual drug monographs for all drugs currently available in the UK to treat TB. These recommendations provide a structure through which healthcare professionals can better manage the complex drug regimens required for the treatment of MDR-TB; minimising the risk of adverse incidents and helping to improve patients’ tolerance, compliance and treatment completion.

Ejemplares similares